We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchison China Meditech Limited | AQSE:HCM.GB | Aquis Stock Exchange | Ordinary Share | KYG4672N1198 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 270.00 | 260.00 | 280.00 | 270.00 | 270.00 | 270.00 | 0.00 | 06:56:53 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMHCM
RNS Number : 5202Q
Hutchison China Meditech Limited
30 November 2016
Exercise of Share Options by a Person Discharging Managerial Responsibilities
London: Wednesday, November 30, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Responsibilities), has exercised 25,535 share options (granted in 2007 and which are soon due to expire in May 2017) over ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an exercise price of GBP1.535 per share on November 25, 2016. Such Ordinary Shares will be held in the form of American Depositary Shares ("ADSs") each representing one half of one Ordinary Share.
Following the above exercise of options and subject to the completion of allotment, the holding of Dr Su is 25,535 Ordinary Shares, representing approximately 0.04% of the current issued share capital of Chi-Med, which he intends to hold as a long term investment. Additionally Dr Su holds a further 300,000 unexercised options which would represent a further 0.49% of the issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated ---- ---------------------------------------------------------------------------------------------------------------- a) Name Dr Weiguo Su ---- ------------------------------------------------------- ------------------------------------------------------- 2 Reason for the notification ---- ---------------------------------------------------------------------------------------------------------------- a) Position/status Executive Vice President and Chief Scientific Officer of Chi-Med ---- ------------------------------------------------------- ------------------------------------------------------- b) Initial notification/Amendment Initial notification ---- ------------------------------------------------------- ------------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ---------------------------------------------------------------------------------------------------------------- a) Name Hutchison China MediTech Limited ---- ------------------------------------------------------- ------------------------------------------------------- b) LEI N/A ---- ------------------------------------------------------- ------------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ---------------------------------------------------------------------------------------------------------------- a) Description of the financial instrument, type of Ordinary Shares of US$1.00 each in the form of ADSs instrument each representing one half of one Ordinary Identification code Share of US$1.00 DI ISIN: KYG4672N1016 ADS ISIN: US44842L1035 ---- ------------------------------------------------------- ------------------------------------------------------- b) Nature of the transaction Exercise of share options on November 25, 2016 at a price of GBP1.535 per share. Such Ordinary Shares will be held in the form of ADSs. ---- ------------------------------------------------------- ------------------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ---------- ---------- GBP1.535 25,535 ---------- ---------- ---- ------------------------------------------------------- ------------------------------------------------------- d) Aggregated information Aggregated volume: 25,535 - Aggregated volume Price information: GBP1.535 - Price ---- ------------------------------------------------------- ------------------------------------------------------- e) Date of the transaction 2016-11-25 ---- ------------------------------------------------------- ------------------------------------------------------- f) Place of the transaction Outside a trading venue ---- ------------------------------------------------------- -------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries Christian Hogg, CEO +852 2121 8200 International Media Enquiries Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk Citigate Dewe Rogerson U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Citigate Dewe Rogerson Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDBLBXQFFZFBV
(END) Dow Jones Newswires
November 30, 2016 02:51 ET (07:51 GMT)
1 Year Hutchison China Meditech Chart |
1 Month Hutchison China Meditech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions